Upadacitinib for the Management of Severe Alopecia Areata in Adolescent Patients: A Single-Centre Retrospective Study

    August 2024 in “ Clinical and Experimental Dermatology ”
    Vincenzo Picone, Paola Nappa, Maddalena Napolitano … Mariateresa Cantelli
    Studysummary In this retrospective study conducted at a trichology clinic, the off-label use of upadacitinib for at least 24 weeks was found to have a promising efficacy and safety profile for treating severe alopecia areata in adolescents.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on doi.org →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Upadacitinib for Management of Recalcitrant Alopecia Areata: A Retrospective Case Series JAAD case reports · 2023
    2. An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata Frontiers in immunology · 2022

    Related research 3

    1. Alopecia Areata: A Multifactorial Autoimmune Condition Journal of autoimmunity · 2018
    2. Linear Alopecia Areata JAAD case reports · 2018
    3. Treating Resistant Cases of Alopecia Universalis Journal of cosmetology & trichology · 2018